Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of “Buy” by Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned a consensus recommendation of “Buy” from the twenty-two ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, nineteen have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $117.60.

KYMR has been the topic of a number of analyst reports. Morgan Stanley reiterated an “overweight” rating and set a $123.00 price objective on shares of Kymera Therapeutics in a research note on Thursday. Truist Financial upped their price target on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Bank of America increased their price target on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Piper Sandler lifted their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Wells Fargo & Company upped their target price on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $95.03 on Friday. The business has a 50-day moving average of $78.37 and a 200-day moving average of $64.89. The stock has a market capitalization of $6.84 billion, a price-to-earnings ratio of -26.47 and a beta of 2.21. Kymera Therapeutics has a fifty-two week low of $19.44 and a fifty-two week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the previous year, the company posted ($0.88) EPS. The business’s revenue was down 60.8% on a year-over-year basis. On average, sell-side analysts expect that Kymera Therapeutics will post -2.79 EPS for the current year.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target to $140 and reaffirmed an “overweight” rating, signaling strong analyst confidence and implying meaningful upside from current levels. Piper Sandler Raise
• Neutral Sentiment: BTIG trimmed its target slightly from $138 to $134 but kept a “buy” rating — a modest adjustment that maintains institutional support but is not a bearish signal. BTIG Note
• Negative Sentiment: Kymera reported Q4 EPS of ($0.97), missing consensus (loss of $0.77) and posted revenue of $2.87M versus estimates near $14.8M; revenue fell ~60.8% year‑over‑year — a material earnings and top-line miss that increases short-term execution risk. Q4 Results
• Negative Sentiment: CEO Nello Mainolfi sold 30,000 shares for ~$2.71M (filed with the SEC). Insider sales can be interpreted negatively by some investors even though the CEO retains a large stake. Insider Sale
• Neutral Sentiment: Technical/contextual note: the stock is trading well above its 50‑ and 200‑day moving averages and near its 52‑week high, reflecting strong momentum that may amplify both positive analyst headlines and headline-driven volatility.

Insider Activity

In related news, insider Jared Gollob sold 49,307 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the transaction, the insider directly owned 109,992 shares of the company’s stock, valued at approximately $9,752,990.64. The trade was a 30.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nello Mainolfi sold 100,000 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00. Following the completion of the sale, the chief executive officer owned 660,482 shares in the company, valued at approximately $58,895,179.94. This trade represents a 13.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 450,895 shares of company stock valued at $40,486,151. 16.01% of the stock is owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KYMR. Virtu Financial LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at about $2,123,000. T. Rowe Price Investment Management Inc. grew its stake in Kymera Therapeutics by 3.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company’s stock valued at $49,001,000 after buying an additional 18,524 shares during the last quarter. Invesco Ltd. raised its holdings in Kymera Therapeutics by 46.3% in the 4th quarter. Invesco Ltd. now owns 116,747 shares of the company’s stock valued at $9,084,000 after acquiring an additional 36,940 shares during the period. Vident Advisory LLC lifted its position in Kymera Therapeutics by 6.5% during the fourth quarter. Vident Advisory LLC now owns 7,581 shares of the company’s stock worth $590,000 after acquiring an additional 465 shares during the last quarter. Finally, Mackenzie Financial Corp bought a new stake in shares of Kymera Therapeutics during the fourth quarter worth approximately $270,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.